Merck Passes Huntington’s RNAi Program To Targeted Genetics
This article was originally published in The Pink Sheet Daily
Executive Summary
Sirna division’s early-stage targets are of lesser interest to the pharma firm, analyst tells “The Pink Sheet” DAILY.